Asset Details
Do you wish to reserve the book?
071 Perampanel as early add-on therapy for focal-onset and generalised-onset seizures in clinical practice
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
071 Perampanel as early add-on therapy for focal-onset and generalised-onset seizures in clinical practice
Do you wish to request the book?
071 Perampanel as early add-on therapy for focal-onset and generalised-onset seizures in clinical practice
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
071 Perampanel as early add-on therapy for focal-onset and generalised-onset seizures in clinical practice
2022
Overview
Data from 44 pooled clinical practice studies were compared for epilepsy patients with focal-onset and/or generalised-onset seizures treated with perampanel (PER) as early (n=632) versus late add-on therapy (n=1900). Retention was assessed after 3, 6 and 12 months of PER treatment. Effectiveness assess- ments comprised responder rate (≥50% seizure frequency reduction), seizure freedom rate and rate of unchanged or worsening seizure frequency. Adverse events (AEs) and discontinuation due to AEs were evaluated. Retention was significantly higher with early versus late add-on therapy at all timepoints. At last visit, seizure freedom rate was significantly higher with early versus late add-on therapy (40.1% vs. 8.7%; p<0.001), as was responder rate (73.0% vs. 36.4%; p<0.001); and the proportion of patients with unchanged seizure frequency was significantly lower in the early versus late add-on group (10.2% vs. 31.8%; p<0.001), as was worsening seizure frequency (6.1% vs. 13.6%; p<0.001). Patients treated with early versus late add-on therapy had a significantly lower incidence of AEs (41.8% vs. 54.5%; p<0.001), psychi- atric AEs (18.3% vs. 22.2%; p=0.046), and discontinuation rates due to AEs at 12 months (15.0% vs.18.7%; p=0.045). In conclusion, PER was significantly more effective and better-tolerated as early add-on therapy in everyday clinical practice.Supported by Eisai.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD
